Iopofosine I-131 (CLR 131)

Verified

Overview

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

SparkCures ID 222
Developed By Cellectar Biosciences
Generic Name Iopofosine I-131 (CLR 131)
Additional Names I-131-CLR1404, CLR131, CLR-131, CLR 131, iopofosine
Treatment Classifications
  • Phospholipid Drug Conjugate (PDC)
Tags

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
CLOVER-1
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
CLOVER-1
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

September 06, 2022

Initial findings from this CLOVER-1 expansion cohort of quad-class refractory (including anti-BCMA immunotherapy) R/RMM patients adds to the body of evidence that fractionated dosing achieving ≥60 mCi total body dose of iopofosine can be safely administered, leading to an ORR of 50%, with stable disease or better for all treated patients. The depth and durability of response to iopofosine in this heavily pretreated, refractory population compares favorably with previous experience with iopofosine and other treatments being used alone in similar patient populations. One limitation of this primary analysis was its small patient cohort and the short duration of follow-up. Continued patient enrollment in this cohort as well as a longer follow-up is needed.

Read More

Resources

Cellectar Biosciences Expanded Access Policy

May 14, 2019

Read More
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post a...

December 01, 2022

Read More
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in th...

December 16, 2019

Read More
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented...

December 09, 2019

Read More
Investigational Therapy Delivers Treatment to Patients with Multiple Myeloma in Two Doses

November 04, 2019

Read More
Cellectar Biosciences’ New Radiosensitive Therapy in Multiple Myeloma with Natalie Callander, MD ...

October 01, 2019

Read More
CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment

September 27, 2019

Read More
CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Re...

May 15, 2019

Read More
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

May 13, 2019

Read More
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongo...

February 25, 2019

Read More
Overall Survival Lengthened for Relapsed/Refractory Myeloma Patients Using CLR 131 Cancer-Targete...

February 02, 2019

Read More
Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

January 07, 2019

Read More
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relaps...

October 02, 2018

Read More
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myelo...

August 20, 2018

Read More
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase...

November 07, 2017

Read More
Phospholipid-Ether Drug Conjugates: A Novel Vehicle Delivering Cytotoxic Small-Molecules

May 26, 2016

Read More
SparkCures Verified

SparkCures is working closely with Cellectar Biosciences to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners